| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Tumor Biology, Karolinska Institute, S 104 01 Stockholm 60, Sweden
Two groups of adult CBA mice were immunized with 107 allogeneic Moloney lymphoma (YAC) cells. These YAC (H-2a) cells, which were either irradiated with 6000 R (Group I) or were formaldehyde fixed (Group II), were injected i.p. at weekly intervals for 3 weeks. Four days following the last injection, sera and lymphocytes were collected and tested in vitro for activity against either allospecific antigens (H-2d target cells) or viral-specific antigens, namely, Moloney leukemia virus (MLV). Both groups of animals developed measurable cellular and humoral immunity to the virally determined antigens. However, only the animals in Group I, immunized with irradiated cells, developed detectable immunity to H-2d. Immune and control lymphocytes were tested in microcytotoxicity tests and by 51Cr release. Antibody was assessed by complement-dependent cytotoxicity, indirect membrane immunofluorescence, virus neutralization, and antibody-dependent lymphocyte cytotoxicity. Group I serum, which had both anti-MLV and anti-H-2 antibodies, was absorbed with either living or formaldehyde-fixed YAC cells. The living cells were able to remove both H-2 and MLV antibodies. On the other hand, the formaldehyde-fixed cells removed no H-2 antibody but were able to remove MLV antibody, although less efficiently than living cells. These data indicate that formaldehyde fixation selectively impaired the H-2 antigens, leaving the viral antigenicity relatively intact. Differences between the immune responses to MLV-determined antigens and to H-2 antigens were demonstrated in many of the parallel in vitro tests.
1 The work upon which this publication is based was performed persuant to Contract N01-CB-33870 within the division of Cancer Biology and Diagnosis, National Cancer Institute, Department of Health, Education and Welfare; The Swedish Cancer Society; and the Jane Coffin Childs Memorial Fund for Medical Research.
2 Supported by NIH Training Grant 50T01 GM01924-3, Clinical Investigators in Surgery, University of Alabama in Birmingham, The Medical Center, Birmingham, Ala. Present address: Departments of Surgery and Microbiology, Cancer Research and Training Center, University of Alabama in Birmingham, School of Medicine, Birmingham, Ala. 35294.
3 Recipient of a USPHS Research Career Development Award. Present address: Cedars of Lebanon Hospital, Department of Pediatrics, Los Angeles, Calif. 90054.
Received 8/26/74. Accepted 12/30/74.
This article has been cited by other articles:
![]() |
M. Okamoto, S. Furuichi, Y. Nishioka, T. Oshikawa, T. Tano, S. U. Ahmed, K. Takeda, S. Akira, Y. Ryoma, Y. Moriya, et al. Expression of Toll-Like Receptor 4 on Dendritic Cells Is Significant for Anticancer Effect of Dendritic Cell-Based Immunotherapy in Combination with an Active Component of OK-432, a Streptococcal Preparation Cancer Res., August 1, 2004; 64(15): 5461 - 5470. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Okamoto, G. Oh-e, T. Oshikawa, S. Furuichi, T. Tano, S. U. Ahmed, S. Akashi, K. Miyake, O. Takeuchi, S. Akira, et al. Toll-Like Receptor 4 Mediates the Antitumor Host Response Induced by a 55-Kilodalton Protein Isolated from Aeginetia indica L., a Parasitic Plant Clin. Vaccine Immunol., May 1, 2004; 11(3): 483 - 495. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |